Targeting Metabolic Scavenging in Pancreatic Cancer

Costas A. Lyssiotis and Lewis C. Cantley

Pancreatic tumor metabolism is rewired to facilitate survival and growth in a nutrient-depleted environment. This leads to a unique dependence on metabolic recycling and scavenging pathways, including NAD salvage. Targeting this pathway in pancreatic cancer disrupts metabolic homeostasis and impairs tumor growth. Clin Cancer Res; 20(1); 6–8. ©2013 AACR.

In this issue of Clinical Cancer Research, Chini and colleagues demonstrate that targeting the NAD salvage pathway in pancreatic cancer cell lines and tumors impairs growth (1), suggesting that such a strategy could find application in humans. This work builds on a rapidly growing body of research and clinical data, which posit that targeting tumor metabolism in pancreatic cancer may bring new treatments for this devastating disease.

A pancreatic cancer diagnosis is a virtual death sentence. The 5-year survival rate is a staggeringly low 6% and median survival is only 6 months (2). These dismal statistics can be attributed in large part to the fact that effective treatment options and targeted agents are not available for this disease. Standard treatment modalities have been largely ineffective in pancreatic cancer due to several factors, among which is that pancreatic cancers exist in a unique metabolic environment. For example, such tumors are extremely dense with interstitial pressures that can exceed ten times those observed in normal organs like the liver or pancreas (3). Pancreatic tumors are also intensely fibrotic, where in many cases less than 10% of the total tumor mass is composed of cancer cells, the remainder being stromal fibroblasts, immune infiltrate, and deposited extracellular matrix. Collectively, these features act to impair vascularization, which makes pancreatic tumors extremely hypoxic and limits nutrient availability, not to mention drug delivery (4). Given this limited access to nutrients and oxygen, it is then no surprise that pancreatic tumor metabolism must adapt to facilitate survival and growth in this challenging metabolic environment.

The well-characterized metabolic adaptations of pancreatic cancer can be generally grouped together into a single category; features which are all underlined by the ability to scavenge and recycle metabolic substrates. For example, pancreatic cancers exhibit a high degree of basal autophagy and they are strictly dependent on this process for growth and survival (5, 6). In addition to the consumption of internal cargo, they also consume lipids (7) and protein (8) from the extracellular space. Such biomolecules are either used directly or broken down into component parts and then used for the maintenance of anabolic metabolism (9). Although these processes can also be observed in normal cells, it is important to note that pancreatic cancers depend on the continued activity of the aforementioned recycling and scavenging pathways. In fact, the dependence of pancreatic cancers on autophagy and extracellular protein eating (a process termed macropinocytosis) were both recently explored in clinical trials. In the case of the former, multiple clinical trials are ongoing in pancreatic cancer to test this approach given the availability of drugs such as hydroxychloroquine (an antirheumatologic drug that has been used safely in people for decades), which inhibits the last step of autophagy by blocking lysosomal function. Whether this will be an effective approach is not yet clear and will depend upon the ability of hydroxychloroquine to achieve therapeutic levels that inhibit autophagy in patients, not to mention that appropriate combination agents remain to be determined (10). In addition, the therapeutic application of a drug that exploits the dependence of pancreatic cancer on macropinocytosis was recently approved for metastatic disease (11). This agent is a protein–drug conjugate [albumin–paclitaxel; termed nab-paclitaxel or known by its trade name Abraxane (Celgene)]. That is presumably delivered to poorly vascularized pancreatic tumors through extracellular protein engulfment, thereby delivering the cytotoxic payload. Indeed, patients on standard of care plus Abraxane were afforded a 2-month increase in median survival, which is seen as major progress in a disease that has not seen significant clinical improvements in decades. Interestingly, these two approaches are also being combined in patients with pancreatic cancer through a Stand Up To Cancer initiative. In this study, patients will receive standard of care (gemcitabine) with Abraxane and hydroxychloroquine. Importantly, these results also demonstrate proof-of-principle that targeting metabolic scavenging pathways holds promise for pancreatic cancer.
Consistent with this framework, the study highlighted herein by Chini and colleagues now describes that pancreatic tumors are also dependent on the salvage of NAD for growth (1). NAD is a cofactor that performs two general functions in cells. It facilitates the shuttling of reducing equivalents generated from metabolic reactions (e.g., from glycolysis to the mitochondria) and can also be catabolized directly, where its metabolites are used to change the post-translational makeup of a cell. Following catabolism, NAD can be generated de novo or it can be recycled through its salvage pathway (Fig. 1). Like other metabolic scavenging pathways in pancreatic cancer, here, too, the salvage pathway is used. This was illustrated by pharmacologically or genetically inhibiting the first step in the NAD salvage pathway governed by nicotinamide phosphoribosyltransferase (NAMPT) and observing a drop in cellular NAD levels. Moreover, utilization of this salvage pathway seems to be another metabolic addiction in pancreatic cancer, as inhibition of NAMPT impairs tumor growth in vitro and in xenograft tumors. The authors go on to demonstrate that the dependence on NAD salvage is for the metabolic use of NAD in transferring reducing potential, rather than as a dependence on NAD salvage is for the metabolic use of xenograft tumors. The authors go on to demonstrate that the impairment of pancreatic cancer growth following NAMPT inhibition can be rescued by using metabolites downstream of NAMPT that bypass pharmacologic inhibition [e.g., nicotinamide mononucleotide (NMN)]. Collectively, these results illustrate that inhibition of NAD salvage results in a metabolic collapse in pancreatic cancer that impairs growth.

In addition to providing further evidence supporting the notion that targeting the disrupted metabolic state in pancreatic cancer may prove efficacious, this study also pinpoints a specific target, NAMPT, for which first-generation clinical grade inhibitors are currently available and have been examined in several tumor contexts. This study also raises the question of whether NAMPT inhibition may synergize with other methods that target metabolic dependencies in pancreatic cancer that are being examined or deployed in the clinical setting (10, 11). Specifically, it has been previously demonstrated that NAD salvage inhibition induces autophagy (12). Given the critical role of autophagy in PDAC survival, it is conceivable that the combination of autophagy suppression and inhibition of NAD salvage may act synergistically. In summary, the observation that NAD salvage is required by pancreatic cancer cells to maintain energy homeostasis provides yet another piece to this interesting metabolic puzzle. Together with the recent clinical assessment of Abraxane and hydroxychloroquine, these results suggest that through targeting the disrupted metabolic state in pancreatic cancer, promising therapies may be in reach for this dreaded disease.

**Disclosure of Potential Conflicts of Interest**
L.C. Cantley is a member of the board of directors and a consultant/advisory board member for Agios Pharmaceuticals, for which he also has ownership interests (including patents). Celgene is an investor in and collaborator with Agios Pharmaceuticals. No potential conflicts of interest were disclosed by the other author.

**Authors’ Contributions**
Conception and design: C.A. Lyssiotis, L.C. Cantley
Writing, review, and/or revision of the manuscript: C.A. Lyssiotis, L.C. Cantley

**Acknowledgments**
The authors thank Drs. Alec Kimmelman (Department of Radiation Oncology, Dana-Farber Cancer Institute) and Haoqiang Ying (Department of Genomic Medicine, MD Anderson Cancer Center) for thoughtful feedback on this commentary.

**Grant Support**
This work is supported in part by a PanCan/AACR Pathway to Leadership Award (to C.A. Lyssiotis) and an NIH P01 CA117969 grant (to L.C. Cantley).

Received October 5, 2013; accepted October 19, 2013; published OnlineFirst October 28, 2013.
References

Clinical Cancer Research

Targeting Metabolic Scavenging in Pancreatic Cancer
Costas A. Lyssiotis and Lewis C. Cantley


Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-13-2570

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2014/01/06/1078-0432.CCR-13-2570.DC1

Cited articles
This article cites 11 articles, 6 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/20/1/6.full.html#ref-list-1

Citing articles
This article has been cited by 1 HighWire-hosted articles. Access the articles at:
/content/20/1/6.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.